Strategic Partnerships Remedy Plan is a clinical-stage biotech focused on NAMPT inhibitors with a lead asset RPT1G advancing to the clinic in 2024 and a healthy press cadence, presenting opportunities for CRO collaborations, contract development and manufacturing, and joint ventures with oncology and metabolic disease players.

Clinical Expansion Recent Phase 1 healthy volunteer results for RPT1G and upcoming AACR presentations indicate a readiness to partner on later-stage clinical trials, enabling pharma and biotech sponsors to explore co-development, translational studies, or licensing for hematologic malignancies and solid tumors.

Financial Capacity With $47M in funding and a recent $18M financing round, Remedy Plan has investor support and runway to engage early strategic partners for milestone-driven deals, potentially reducing risk for collaborators while accelerating non-dilutive options.

Leadership Engagement New executive appointments including a Chief Financial and Business Officer and an expanding leadership team signal a readiness to engage in complex deal structuring, financial diligence, and scalable operations for partnering opportunities.

Industry Positioning Remedy Plan’s emphasis on tunable NAMPT inhibition with reduced on-target toxicity positions it uniquely within oncology and metabolic disease spaces, suggesting outreach to biopharma companies seeking differentiated NAMPT-modulating therapies and related biomarkers for companion diagnostics.